For use in adult patients and children aged 4 years and older
baclofen
Lioresal Intrathecal contains the active substance baclofen. Lioresal Intrathecal is a medicine used for
excessive muscle tension.
Lioresal Intrathecal is used to treat severe, chronic spasticity (increased muscle tone)that cannot be effectively treated with standard medicines:
During the qualification phase for treatment and during the dose escalation phase, immediately after the pump is implanted, the patient will be closely monitored in conditions that ensure access to appropriate equipment and staff care. The dosage, possible side effects, or signs of infection will be regularly evaluated. The functioning of the drug delivery system will also be checked.
If there is no improvement or the patient feels worse, they should consult a doctor.
The patient should consult their doctor immediately if they think the device is not working properly or if they notice withdrawal symptoms (see withdrawal symptoms in section 3 "How to use Lioresal Intrathecal")
If any of the following points apply to the patient, they should tell their doctor before starting to use Lioresal Intrathecal:
If any of these symptoms occur during the use of Lioresal Intrathecal, the patient should immediately inform their doctor:
Children
Children should meet certain requirements regarding adequate body weight to allow for the implantation of an infusion pump. Lioresal Intrathecal is intended for use in children aged 4 years and older. The safety of intrathecal use of Lioresal Intrathecal in children under 4 years of age has not been established yet.
Patient over 65 years of age
During clinical trials, Lioresal Intrathecal was administered to several elderly patients and did not cause particular problems. However, experience with the use of Lioresal in tablet form shows that this group of patients may be more prone to side effects. Therefore, elderly patients should be closely monitored for side effects.
The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
The following medicines may affect the action of Lioresal Intrathecal or Lioresal Intrathecal may interact with them. It may be necessary to adjust the dose of Lioresal Intrathecal or one of the other medicines taken at the same time:
When using Lioresal Intrathecal, the patient should avoid consuming alcohol at the same time, as this may cause undesirable intensification or unpredictable changes in the action of the medicine.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor before using this medicine.
Due to the lack of experience with pregnant and breastfeeding women, Lioresal Intrathecal can only be used if the doctor considers it absolutely necessary.
Do not drive vehicles, operate machines, or perform other hazardous activities, as Lioresal Intrathecal may significantly affect these activities.
Lioresal Intrathecal 10 mg/20 ml: the medicine contains 70.81 mg of sodium (main component of table salt) per 20 ml. This corresponds to 3.5% of the maximum recommended daily sodium intake in the diet for adults.
Lioresal Intrathecal 10 mg/5 ml: the medicine contains less than 1 mmol (23 mg) of sodium per 5 ml, i.e., the medicine is considered "sodium-free".
If the doctor needs to dilute Lioresal Intrathecal 10 mg/5 ml with a saline solution, the resulting sodium dose will be higher.
This medicine should always be used exactly as prescribed by the doctor. If the patient has any doubts, they should consult their doctor or pharmacist.
Lioresal Intrathecal can be administered by direct injection or infusion into the spinal canalonly by a qualified specialist and with the help of appropriate equipment.
Therefore, hospitalization is necessary at the beginning of treatment.
At the beginning of treatment, the doctor will determine whether a single injection of the medicine in a smaller dose - Lioresal Intrathecal, 0.05 mg/1 ml, solution for injection - will relieve muscle spasms. If possible, a special pump will be implanted under the patient's skin, which will allow for continuous dosing tailored to the patient.
It is very important for the patient to attend scheduled appointments, during which the doctor will refill the pump.
If the patient receives too small a dose of Lioresal Intrathecal, increased muscle tone may return. Muscle spasms may also worsen.
The patient should immediately tell their doctorif muscle spasms do not improve or worsen.
The doctor must regularly monitor the patient's condition and the pump's function - at least once a month.
The duration of treatment will be decided by the doctor.
The patient should immediately contact their doctorif they or their caregiver notice symptoms of overdose, which can occur suddenly or gradually:
If it is necessary to stop the administration of the medicine, this can only be done by the attending doctor, who will gradually reduce the dose of the medicine to avoid side effects. Abrupt cessation of Lioresal Intrathecal may cause severe side effects, which in a few cases have been fatal.
The patient should immediately contact their doctorif they or their caregivers notice the following withdrawal symptomsof Lioresal Intrathecal. This is especially important for further administration through the pump.
The patient should remember that pump malfunctions, such as battery problems or catheter defects, alarm signal defects, or device malfunctions, can lead to overdose or underdose of the medicine.
If the patient has any doubts about the use of the medicine, they should consult their doctor.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Side effects are more common during the initiation of treatment in the hospital, but they can also occur later. Many of the listed side effects may also be related to the underlying disease being treated.
Malfunction of the implanted device delivering the medicine or the infusion system can lead to withdrawal symptoms, which can be life-threatening (see withdrawal symptoms in section 3 "How to use Lioresal Intrathecal").
The following side effects have been reported, along with their frequency:
Very common: may occur in more than 1 in 10 patients
Common: may occur in up to 1 in 10 patients
Uncommon: may occur in up to 1 in 100 patients
Rare: may occur in up to 1 in 1,000 patients
*Side effects marked with an asterisk occur more frequently in patients with cerebral palsy.
If the patient experiences any side effects, including any possible side effects not listed in the leaflet, they should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products
Aleje Jerozolimskie 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Reporting side effects will help gather more information on the safety of the medicine.
The medicine should be stored in a place that is out of sight and reach of children.
Do not store above 30°C.
Do not freeze. Do not sterilize with high temperature.
The medicine should be used immediately after opening. Unused solution should be discarded.
The solution must be clear and colorless. Do not use this medicine if cloudiness or discoloration is observed.
Do not use this medicine after the expiry date stated on the ampoule and carton. The expiry date refers to the last day of the month stated.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
6.
Lioresal Intrathecal 10 mg/20 ml solution for infusion:
1 ml of the solution for infusion contains 0.5 mg of baclofen.
1 ampoule with 20 ml of the solution for infusion contains 10 mg of baclofen.
Lioresal Intrathecal 10 mg/5 ml solution for infusion:
1 ml of the solution for infusion contains 2.0 mg of baclofen.
1 ampoule with 5 ml of the solution for infusion contains 10 mg of baclofen.
Lioresal Intrathecal is a clear, colorless solution in a transparent, colorless ampoule.
Lioresal Intrathecal 10 mg/20 ml solution for infusion and Lioresal Intrathecal 10 mg/5 ml solution for infusion are available in packs containing 1, 2, or 5 ampoules.
Not all pack sizes may be marketed.
Novartis Poland Sp. z o.o.
ul. Marynarska 15
02-674 Warsaw
phone: +48 22 37 54 888
Novartis Pharma GmbH
Roonstrasse 25
D-90429 Nürnberg
Germany
Novartis Pharma GmbH
Sophie-Germain-Strasse 10
90443 Nuremberg
Germany
Novartis Farmacéutica S.A.
Gran Via de les Corts Catalanes, 764
08013 Barcelona
Spain
Novartis Poland Sp. z o.o.
ul. Marynarska 15
02-674 Warsaw
Germany:
Lioresal Intrathecal 10 mg/20 ml Infusionslösung
Lioresal Intrathecal 10 mg/5 ml Infusionslösung
Poland:
Lioresal Intrathecal 10 mg/20 ml, solution for infusion
Lioresal Intrathecal 10 mg/5 ml, solution for infusion
________________________________________________________________________
The administration of a test dose, implantation of the infusion pump, and dose escalation of the medicinal product administered intrathecally should be performed in a hospital setting, in centers with appropriate experience and under the close supervision of qualified physicians. Immediate access to an intensive care unit should be ensured due to the possibility of severe or life-threatening side effects of the medicinal product.
Before starting the administration of Lioresal Intrathecal, the clarity and colorlessness of the solution should be checked. If the solution is cloudy or discolored, the medicinal product should not be administered.
Each ampoule is intended for single use only. The solution it contains is stable, isotonic, free of pyrogens and antioxidants, with a pH of 5.0-7.0.
After confirming the patient's response to Lioresal Intrathecal therapy in the test phase, intrathecal infusion of the medicinal product can be started using the aforementioned infusion pump. The antispastic effect of baclofen begins within 6 to 8 hours after the start of continuous infusion, and the maximum effect of the medicine is observed after 24 to 48 hours.
The initial total daily dose of Lioresal Intrathecal is calculated as follows: if the effect of the medicine after the test dose lasts more than 12 hours, this dose is considered the initial dose. If the effect of the medicine after the test dose lasts less than 12 hours, the test dose should be doubled and administered as the initial dose. The dose of the medicine should not be increased during the first 24 hours of treatment.
After the first day of treatment, the dose of the medicine can be gradually increased to achieve the desired therapeutic effect. The daily dose should not be increased by more than 10% to 30% of the previous dose in patients with spinal cord spasticity and 5% to 15% in patients with cerebral spasticity. When using a programmable pump, it is recommended to modify the dose only once every 24 hours. When using non-programmable pumps equipped with a 76 cm catheter, which delivers 1 ml of solution per day, it is recommended to assess the patient's response to the new dose after 48 hours. If a significant increase in the daily dose does not result in increased clinical efficacy, the proper functioning of the pump and catheter patency should be checked.
Essentially, the dose of Lioresal Intrathecal is increased to achieve a maintenance dose in the range of 300 μg to 800 μg per day in patients with spinal cord spasticity. Patients with cerebral spasticity usually require smaller doses (see below).
The goal of treatment is to use the smallest dose that provides good control of spasticity without unacceptable side effects. Since the therapeutic effect may decrease during treatment, and the severity of spasticity may change, it is usually necessary to adjust the dose in a hospital setting during long-term therapy.
Also, in this case, the daily dose can be increased by 10% to 30% in patients with spinal cord spasticity and 5% to 20% (upper limit) in patients with cerebral spasticity by changing the infusion rate or the concentration of baclofen in the pump reservoir. And vice versa, if side effects occur, the daily dose of Lioresal Intrathecal can be decreased by 10% to 20%.
The need for sudden dose escalation to achieve the desired therapeutic effect suggests possible pump malfunction or catheter kinking, cracking (abrasion), or displacement.
The maintenance dose of Lioresal Intrathecal in long-term therapy in patients with spinal cord spasticity is usually 300 μg to 800 μg of baclofen per day.
The smallest and largest registered daily doses administered to individual patients during the loading phase were 12 μg and 2003 μg, respectively (studies conducted in the United States). Experience with doses exceeding 1000 μg per day is limited. During the first few months of treatment, the dose of Lioresal Intrathecal should be verified and modified, especially frequently.
In the case of patients with cerebral spasticity, the maintenance doses used during long-term therapy with continuous infusion of Lioresal Intrathecal are in the range of 22 μg to 1400 μg of baclofen per day, and the average daily doses of the medicinal product are 276 μg after 1 year of observation and 307 μg after 2 years. Children under 12 years of age usually require smaller doses (range: 24 μg to 1199 μg per day; average: 274 μg per day).
If the technical parameters of the pump allow, after determining the daily dose of the medicinal product and stabilizing the antispastic effect, it is possible to try to adjust the administration of the medicinal product to the daily rhythm of spasticity. For example, if spasms occur more frequently at night, this may require a 20% increase in the infusion rate for one hour. Changes in the infusion rate should be programmed to occur 2 hours before the desired clinical effect.
Throughout the treatment period, regular, at least monthly, monitoring of the patient's tolerance to Lioresal Intrathecal and possible signs of infection is necessary in the treatment center. The proper functioning of the infusion system should be regularly checked. The development of local infection or catheter malfunction can lead to a break in intrathecal administration of Lioresal Intrathecal with life-threatening consequences for the patient.
The concentration of baclofen required during pump filling depends on the total daily dose of the medicinal product and the infusion rate of the pump. If it is necessary to administer baclofen in concentrations other than 0.05 mg/ml, 0.5 mg/ml, or 2 mg/ml, Lioresal Intrathecal should be diluted under aseptic conditions using a sterile, preservative-free sodium chloride solution for injection. In this case, the instructions provided by the pump manufacturer should be followed.
About 5% of patients may require a higher dose of the medicinal product due to decreased efficacy of treatment ("development of tolerance") during long-term treatment. As described in the literature, the development of tolerance is prevented by a 10- to 14-day break in baclofen administration, during which preservative-free morphine sulfate is administered. After this period, the patient may respond to treatment with Lioresal Intrathecal again. Treatment should be resumed by administering the initial dose used in continuous infusion, and then the dose should be gradually increased again to avoid side effects due to overdose. This procedure should be performed in a hospital setting.
Lioresal Intrathecal 10 mg/20 ml and 10 mg/5 ml solutions for infusion should not be mixed with other solutions for injection or infusion, except for a sterile, preservative-free sodium chloride solution, diluted under aseptic conditions.
A chemical incompatibility has been demonstrated between dextrose and baclofen.
Do not freeze. Do not sterilize with high temperature
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.